Objective: This article reviewed the collective evidence from routine clinical practice to
summarize the existing literature on the effectiveness of rosuvastatin in treating …

Abstract Guidelines from the National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III) focus the need for the most intensive efforts to lower low-density …

Objective: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-
density lipoprotein cholesterol (LDL-C) and LDL‑C goal attainment among patients with type …

BACKGROUND:: The dose range for rosuvastatin in Europe has recently been expanded to
5 to 40 mg and is now in line with the dose range currently available in the United States …

BACKGROUND:: Rosuvastatin is a new statin indicated to reduce elevated levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase …

BACKGROUND: Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the
risk of coronary heart disease. The introduction of a highly efficacious new statin …

Rosuvastatin, a new hydrophilic 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase
inhibitor (statin), is approved as an adjunct to diet in patients with primary …

Background: There is an increasing body of evidence to support the benefits of reducing low-
density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of …

The aim of this multi-center, open-label, randomized, parallel-group trial was to compare the
efficacy of rosuvastatin with that of simvastatin in achieving the 1998 European …

Background Data from Western comparative trials suggest that rosuvastatin is more effective
than atorvastatin, simvastatin, and pravastatin in helping hypercholesterolemic patients …